Beam Therapeutics’ CFO Terry-Ann Burrell will be leaving the company effective August 9 to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase. As part of a transition process, the company has initiated a search for a successor.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Fly Insider: RH, Chewy among this week’s notable insider trades
- Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
- Beam Therapeutics announces dosing of first patient with BEAM-302
- Beam Therapeutics Stock (NASDAQ:BEAM): The Future of Gene Editing?
- Beam Therapeutics reports data from BEAM-101 trial